10X GENOMICS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Directors: Election of the one Class II director listed in the accompanying proxy statement, to serve a three-year term expiring at the 2027 annual meeting of stockholders or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal; Kimberly J. Popovits

10X GENOMICS INC.’s own tally for this item (“Elect Director: Kimberly J. Popovits”): 198,553,136 for, 18,689,301 against, per its Form 8-K filed June 13, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 40,144,209 for, 7,034,283 against.

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

Description as filed by funds: A vote to approve an amendment to our amended and restated bylaws such that the bylaws may be amended by our board of directors without requiring stockholder approval;

10X GENOMICS INC.’s own tally for this item (“3. Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval”): 112,727,437 for, 104,506,389 against — failed, per its Form 8-K filed June 13, 2024 (Item 5.07). This item required more than a simple majority of votes cast — see the filing.

Reported outcome: Not approved, in the filing’s own words: “Proposal 3 - Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval The Company's stockholders did not approve a proposed amendment to the Company'…”
A stricter vote than a majority of the votes cast may have applied to this item; the filing does not state it.
Support: 51.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 11,455,634 for, 35,722,858 against.

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

Description as filed by funds: A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers; and

10X GENOMICS INC.’s own tally for this item (“4. Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers”): 180,775,070 for, 36,417,839 against — passed, per its Form 8-K filed June 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in more detail in the Company's definitive proxy state…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 74 managers: 33,736,240 for, 13,423,075 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 291 managers: 30,220,671 for, 31,993,744 against, 30,065 withheld, 503,687 abstained, 9,803 not voted, 46 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;

10X GENOMICS INC.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 228,845,897 for, 174,119 against — passed, per its Form 8-K filed June 13, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 77 asset managers below reported 47,178,492 for.

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.